Checking Augmentin and Generic Product Identity

How to Check Augmentin Product Identity Before Relying on Appearance

The first step in checking an Augmentin product is to compare its dispensing label with the prescription. The medicine should be identified as Augmentin or amoxicillin and clavulanate potassium, not plain amoxicillin. Both active ingredients must be present in the intended combination product.

Next, confirm the complete strength. Conventional Augmentin tablets use pairs such as 250 mg/125 mg, 500 mg/125 mg and 875 mg/125 mg. The first number identifies amoxicillin, and the second identifies clavulanic acid. A label showing only 500 mg of amoxicillin does not establish that the medicine contains the prescribed combination.

Dosage form is another essential identifier. Conventional tablets, chewable tablets, standard oral suspensions, Augmentin XR and Augmentin ES-600 are distinct products. Some share amoxicillin amounts while differing in clavulanate content, formulation or release characteristics. A correct-looking package must still be checked against the prescribed form.

After confirming the medicine and strength, the pharmacist can compare the actual product with its manufacturer or labeler record. A complete check may involve the imprint, NDC, product name, FDA application, expiration information and package history. These details provide corroborating evidence but do not independently authenticate the physical medicine.

Differences in packaging are not automatically evidence of counterfeiting. A pharmacy may dispense an approved generic, use a different supplier or transfer tablets from a manufacturer stock bottle into a patient-labeled container. The pharmacy should be able to explain the actual product dispensed.

If the label, active ingredients, strength or dosage form cannot be reconciled with the prescription, the medicine should not be used until the pharmacist resolves the discrepancy.

Augmentin Pill Identification: FDA-Labeled Brand and Generic Imprints

The July 2026 FDA Augmentin prescribing information identifies distinct imprints for the original branded conventional tablets. The 250 mg/125 mg and 500 mg/125 mg tablets are described as white, oval, film-coated products with AUGMENTIN on one side and the complete strength on the other. The branded 875 mg/125 mg tablet is white, capsule-shaped and scored, with AUGMENTIN 875 on one side.

Generic amoxicillin/clavulanate tablets can use different markings. For example, a published DailyMed label for Sandoz-manufactured products describes 250 mg/125 mg tablets marked GGN5, 500 mg/125 mg tablets marked GGN6 and 875 mg/125 mg tablets marked GGN7. These markings identify the specific products described in that labeling, not every approved generic.

Tablet imprints are useful because a pharmacist can compare them with a specific labeling record. However, an imprint is not a security feature or laboratory test. A counterfeit product could imitate a legitimate imprint, and a genuine product might look unfamiliar because the pharmacy supplied a different approved manufacturer.

Color and shape are also insufficient on their own. A white, oval tablet could correspond to many medicines, and a capsule-shaped tablet is not necessarily a capsule dosage form. The actual imprint must be interpreted with the full strength, manufacturer or labeler and dispensing information.

The table below gives documented examples from official labeling. They are identification references, not a complete U.S. imprint database or proof that the listed products are currently stocked.

If a tablet does not match the expected description, the appropriate response is to contact the dispensing pharmacist rather than identify it solely through an image search.

How to Verify an Augmentin NDC Without Mistaking It for FDA Approval

The National Drug Code, or NDC, is a three-segment identifier used in the U.S. drug-listing system. Its segments identify the labeler, product and package. These components help distinguish different strength, dosage-form and packaging configurations, but the NDC is not an authentication certificate.

The FDA states explicitly that assignment of an NDC does not denote FDA approval. NDC Directory entries contain information submitted by labelers, and inclusion in the directory does not mean the FDA has independently verified the submitted information. A suspicious package bearing a plausible NDC cannot be declared genuine merely because the number exists in an official database.

The Orange Book serves a different purpose. It identifies drug products approved under an NDA or ANDA and provides therapeutic-equivalence evaluations for applicable multisource prescription medicines. The correct drug name, strength, dosage form and application details should be checked against the product being investigated.

DailyMed supplies product-specific labeling records, which may identify NDCs, physical tablet descriptions, ingredients and the labeler. A labeler can be a manufacturer, distributor, relabeler or repackager, so the company on a pharmacy package need not be identical to the application holder listed in the Orange Book.

NDCs may also be represented in different standardized formatting arrangements for billing or data exchange. A discrepancy in formatting should be reviewed by someone familiar with the source record rather than automatically treated as proof of a counterfeit product.

The safest interpretation comes from using the databases together. The Orange Book supports approval verification, DailyMed and the NDC Directory support labeling and package identification, and the pharmacist verifies the actual medicine and dispensing history.

The FDA approval guide provides the broader catalog of Augmentin applications and generic-equivalence records.

Why Authentic Generic Augmentin Packaging Can Look Different

Original branded Augmentin and approved generic amoxicillin/clavulanate products do not have to use identical packaging or tablet designs. Generic products may differ in color, shape, imprint, coating and certain inactive ingredients while meeting the applicable FDA approval requirements.

The company printed on the dispensed packaging may perform a different role from the FDA application holder. A manufacturer produces the drug, an NDA or ANDA holder is responsible for the approved application, and a distributor or repackager may supply the product under a separate label. These distinctions explain why different legitimate company names can appear across Orange Book, DailyMed and pharmacy records.

A repackager may assign its own NDC to a package containing medication sourced from an approved manufacturer. The corresponding FDA approval relationship must be evaluated using the underlying product record. A new NDC or different distributor name does not automatically indicate a different active-ingredient formulation.

A pharmacy may also dispense tablets from a manufacturer stock bottle into a smaller patient-specific container. In that case, the patient bottle may carry the dispensing pharmacy's label rather than reproduce every detail from the original manufacturer package. The pharmacy should retain the information needed to identify the actual product, including relevant lot and supplier records.

A brand-looking tablet is not necessarily proof that the medicine was supplied through the original brand's current commercial channel. Likewise, a generic-looking tablet is not evidence of inferior quality. Reliable verification requires the complete product identity and appropriate dispensing documentation.

If a patient receives a different manufacturer or package from a previous fill, the pharmacist can explain the product record and confirm whether it corresponds to the prescription. Appearance changes should be investigated when unexpected, not automatically classified as counterfeit.

Individual manufacturer and ANDA-holder information belongs in the Augmentin generic manufacturers directory. This section focuses on the packaging implications of those different company roles.

Identifying Chewable Tablets, Suspension, XR and ES-600 Correctly

Conventional tablet imprints cannot be applied to every Augmentin formulation. Chewable tablets have separate physical descriptions, while oral suspensions are identified primarily through their packaging, active-ingredient concentrations and product labels rather than a tablet imprint.

The July 2026 FDA Augmentin prescribing information describes branded chewable tablets with markings including BMP 189, AUGMENTIN 200, BMP 190 and AUGMENTIN 400 for their respective strengths. These are branded labeling examples; approved generic chewables may have different markings.

Standard oral suspension is supplied as powder for reconstitution in concentrations of 125 mg/31.25 mg, 200 mg/28.5 mg, 250 mg/62.5 mg and 400 mg/57 mg per 5 mL. The product label should specify both ingredients and the concentration after preparation. A bottle color, flavor or volume cannot independently establish which concentration it contains.

Augmentin ES-600 is a separate 600 mg/42.9 mg per 5 mL pediatric suspension. Its package identifiers must not be confused with standard liquid products. Augmentin XR is a 1,000 mg/62.5 mg extended-release bilayer tablet with distinct markings and release characteristics.

The preparation state of an oral suspension is important for a product check. Unreconstituted powder and prepared liquid have different storage requirements, and a bottle that has been mixed must have an appropriate preparation and discard history. Physical appearance cannot establish whether the required conditions were maintained.

A mismatch involving XR, ES-600 or another noninterchangeable formulation requires pharmacist and prescriber review. A product should not be changed solely because an alternative looks similar or has a nearby amoxicillin strength.

Detailed formulation information belongs in the chewable guide, suspension guide, XR guide and ES-600 guide.

Warning Signs of a Suspicious Augmentin Product or Package

A discrepancy in packaging, tablet appearance or dispensing information may indicate a product-identification error, damaged medicine, inappropriate handling or a potentially counterfeit product. FDA advises consumers to pay attention when a medicine looks different from the product they normally receive, particularly when it comes from an unfamiliar or unsafe online source.

Potential warning signs include inconsistent ingredient or strength information, a product name that does not match the prescription, missing or contradictory labeling, damaged seals, evidence of tampering, unclear expiration information or packaging that cannot be reconciled with the pharmacy's records. None of these observations independently proves counterfeiting, but they justify professional review.

A tablet with an unexpected imprint may be an approved generic from another manufacturer. Conversely, a suspicious product could imitate a legitimate imprint and package. An apparent visual match is therefore not sufficient to establish chemical composition, quality or authenticity.

A particularly important concern is a mismatch between plain amoxicillin and amoxicillin/clavulanate. A package that omits clavulanate from the active ingredients should not be treated as Augmentin merely because it contains the prescribed amoxicillin amount.

FDA also identifies online sellers that dispense prescription medicines without a valid prescription or appropriate pharmacy oversight as warning signs. A polished website, low advertised price or published NDC does not establish that the seller is legitimate. General selection of online pharmacies is addressed in the Augmentin online pharmacy guide.

When a product appears suspicious, the patient should avoid using it until the dispensing pharmacist has reviewed the discrepancy. The pharmacy may need to examine the container, product identifier, lot, source and relevant dispensing records.

Lot Numbers, Expiration Dates and Storage-Related Product Concerns

Package authenticity and product integrity are related but different questions. A genuine FDA-approved medicine may become unsuitable if it is expired, improperly stored, damaged or prepared incorrectly. A correct NDC and familiar imprint do not establish that the medicine has remained within its labeled storage conditions.

Lot numbers and expiration dates are useful for product traceability. Depending on how the pharmacy dispenses the medicine, some manufacturer information may appear on the original package rather than the patient-facing container. The pharmacist can use dispensing records to investigate a specific product and lot when necessary.

The July 2026 FDA Augmentin labeling specifies storage at or below 25°C (77°F) for tablets, chewables, XR tablets and unreconstituted powder. Prepared standard Augmentin suspension and ES-600 must be kept refrigerated in the original container, and unused prepared liquid discarded after 10 days.

A prepared suspension therefore requires verification of the reconstitution date as well as the underlying product's identity. Its labeled discard date is not established solely by the manufacturer's expiration date printed on an unreconstituted powder bottle.

A slight color change during storage of prepared Augmentin suspension can be normal according to FDA labeling. However, color, odor or apparent consistency cannot prove that appropriate storage conditions were maintained. Leakage, unusual separation, packaging damage or suspected temperature exposure should be discussed with the pharmacist.

Patients should not extend the life of a prepared suspension, add extra water, transfer it to an unverified container or use leftover antibiotics for another illness. Storage concerns must be resolved independently from the question of whether the product's FDA application and package identifiers are valid.

The Augmentin delivery guide provides additional detail about shipping conditions and the distinction between dry powder and prepared suspension.

Augmentin Authenticity Checklist: What to Do When Something Does Not Match

A reliable product check combines prescription information, physical inspection, authoritative database records and pharmacy confirmation. No single visible identifier should be used as a final authenticity determination.

Begin with the dispensing label and confirm the two active ingredients, complete strength pair, dosage form and quantity. A plain amoxicillin product, conventional tablet, chewable, XR or ES-600 should not be accepted as another category simply because part of the name or amoxicillin amount matches.

Next, review the product's identifying details. For tablets, note the imprint and dosage-form description. For oral suspensions, note the labeled concentration, final bottle volume and whether the powder has been reconstituted. Where available, record the NDC, labeler, lot number and expiration information.

The FDA Orange Book can then be used to verify the relevant approval record, while DailyMed and the NDC Directory can help reconcile labeling and package identifiers. A mismatch between sources should prompt clarification rather than a conclusion that the product is counterfeit.

If concerns remain, contact the dispensing pharmacy before taking the medicine. The pharmacist may be able to check the supplier, actual dispensed product, lot details and manufacturer information. If a product-quality or authenticity problem is suspected, FDA accepts reports through MedWatch. FDA advises that consumers should not send medication samples unless the agency specifically requests them.

An unresolved identification issue should not lead to independently replacing the medicine, opening capsules, combining tablets or using leftover antibiotics. If the problem affects access to a prescribed treatment, the pharmacist and prescriber should determine the appropriate next steps.

The essential distinction is between verifying a regulatory record and authenticating a physical product. Official records provide valuable evidence, but confirmation of an individual medicine may require pharmacy investigation and, in some cases, further manufacturer or regulatory assessment.